Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran (Q85232153)
Jump to navigation
Jump to search
scientific article published on 28 May 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran |
scientific article published on 28 May 2015 |
Statements
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran (English)
Jeffrey I Weitz
Jerrold H Levy
Menno V Huisman
Charles V Pollack
Paul A Reilly
Richard Bernstein
Robert Dubiel
John Eikelboom
Stephan Glund
Elaine Hylek
Chak-Wah Kam
Pieter W Kamphuisen
Joerg Kreuzer
Frank Sellke
Joachim Stangier
Thorsten Steiner